StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Lumigan/Ganfort (bimatoprost) by Quarter

Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M) ($M)

QuarterlyAnnual

AbbVie Lumigan/Ganfort (bimatoprost): $47M in Q4 2025, down 19.0% from a year earlier.

Latest, Q4 2025
47
Period ended Dec 31, 2025
Change on a year earlier
-19.0%
58 in Q4 2024
History
27 quarters
Since Q2 2019
Sources
22
Documents cited below

Where the Q4 2025 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLumigan/Ganfort (bimatoprost) — U.S. net revenues ($M) ($M)Year on yearSource
Q4 2025Dec 31, 202547-19.0%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 202542-27.6%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202552+23.8%Form 10-Q (filed 2025-08-04) ↗
Q1 2025Mar 31, 202548+65.5%Form 10-Q (filed 2025-05-09) ↗
Q4 2024Dec 31, 202458+87.1%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 202458+107.1%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202442-17.6%Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 202429-54.0%Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 202331-44.6%Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 202328-52.5%Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 202351-15.0%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 202363-6.0%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 202256-22.2%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 202259-6.3%Form 10-Q (filed 2023-11-06) ↗
Q2 2022Jun 30, 202260-16.7%Form 10-Q (filed 2023-08-07) ↗
Q1 2022Mar 31, 202267+1.5%Form 10-Q (filed 2023-05-05) ↗

Breakdown

What makes up lumigan/Ganfort (bimatoprost)

Cite this data

StockData. (2026). AbbVie Lumigan/Ganfort (bimatoprost) ($M), quarterly Q2 2019–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lumigan-us

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.